Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The presentations will focus on Reqorsa as a potential treatment for Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. Three posters will be presented, showcasing studies conducted with academic partners.
Genprex has filed two provisional patent applications based on the data, one for treating mesothelioma and another for glioblastoma. The company is co-owner of these applications with the respective institutions. Reqorsa uses the TUSC2 tumor suppressor gene encapsulated in non-viral lipid-based nanoparticles, designed to target cancer cells while minimizing uptake by normal tissue.
Genprex (NASDAQ: GNPX) ha annunciato che i suoi collaboratori di ricerca presenteranno dati preclinici positivi sulla terapia genica Reqorsa® al simposio EORTC-NCI-AACR 2024. Le presentazioni si concentreranno su Reqorsa come trattamento potenziale per il cancro al polmone resistente agli inibitori di Ras, il mesotelioma e il glioblastoma. Saranno presentati tre poster, che mostreranno studi condotti con partner accademici.
Genprex ha depositato due domande di brevetto provvisorie basate sui dati, una per il trattamento del mesotelioma e un'altra per il glioblastoma. La società è co-proprietaria di queste domande con le rispettive istituzioni. Reqorsa utilizza il gene soppressore tumorale TUSC2 incapsulato in nanoparticelle lipidiche non virali, progettato per colpire le cellule cancerose riducendo al minimo l'assorbimento da parte dei tessuti normali.
Genprex (NASDAQ: GNPX) anunció que sus colaboradores de investigación presentarán datos preclínicos positivos sobre la terapia génica Reqorsa® en el Simposio EORTC-NCI-AACR 2024. Las presentaciones se centrarán en Reqorsa como un tratamiento potencial para el cáncer de pulmón resistente a inhibidores de Ras, mesotelioma y glioblastoma. Se presentarán tres carteles, que mostrarán estudios realizados con socios académicos.
Genprex ha presentado dos solicitudes de patente provisional basadas en los datos, una para tratar el mesotelioma y otra para el glioblastoma. La compañía es copropietaria de estas solicitudes con las respectivas instituciones. Reqorsa utiliza el gen supresor tumoral TUSC2 encapsulado en nanopartículas lipídicas no virales, diseñado para dirigirse a las células cancerosas mientras minimiza la absorción por parte del tejido normal.
Genprex (NASDAQ: GNPX)은 그 연구 협력자들이 2024 EORTC-NCI-AACR 심포지엄에서 Reqorsa® 유전자 요법에 대한 긍정적인 전임상 데이터를 발표할 것이라고 발표했습니다. 발표는 Ras 억제제 내성 폐암, 중피종 및 신경교종에 대한 잠재적인 치료제로 Reqorsa에 집중할 것입니다. 세 개의 포스터가 발표되어 학술 파트너와 함께 수행된 연구를 보여줄 것입니다.
Genprex는 이 데이터를 기반으로 두 개의 임시 특허 출원을 제출했습니다. 하나는 중피종 치료를 위한 것이고, 다른 하나는 신경교종에 대한 것입니다. 이 회사는 해당 기관과 함께 이 출원의 공동 소유자입니다. Reqorsa는 TUSC2 종양 억제 유전자를 비유전자 나노입자에 캡슐화하여 설계된 것으로, 암세포를 표적하고 정상 조직에 의한 흡수를 최소화합니다.
Genprex (NASDAQ: GNPX) a annoncé que ses collaborateurs de recherche présenteront des données précliniques positives sur la thérapie génique Reqorsa® lors du Symposium EORTC-NCI-AACR 2024. Les présentations se concentreront sur Reqorsa comme un traitement potentiel pour le cancer du poumon résistant aux inhibiteurs de Ras, le mésothéliome et le glioblastome. Trois affiches seront présentées, mettant en avant des études réalisées avec des partenaires académiques.
Genprex a déposé deux demande de brevet provisoire basées sur ces données, l'une pour le traitement du mésothéliome et l'autre pour le glioblastome. La société est copropriétaire de ces demandes avec les institutions respectives. Reqorsa utilise le gène suppresseur tumoral TUSC2 encapsulé dans des nanoparticules lipidiques non virales, conçu pour cibler les cellules cancéreuses tout en minimisant l'absorption par le tissu normal.
Genprex (NASDAQ: GNPX) gab bekannt, dass seine Forschungspartner positive präklinische Daten zur Reqorsa® Gentherapie im Rahmen des EORTC-NCI-AACR-Symposiums 2024 präsentieren werden. Die Präsentationen werden sich auf Reqorsa als potenzielle Behandlung für Ras-Inhibitor-resistente Lungenkrebserkrankungen, Mesotheliom und Glioblastom konzentrieren. Drei Poster werden präsentiert, die Studien zeigen, die in Zusammenarbeit mit akademischen Partnern durchgeführt wurden.
Genprex hat zwei vorläufige Patentanmeldungen auf Basis dieser Daten eingereicht, eine zur Behandlung von Mesotheliom und eine weitere für Glioblastom. Das Unternehmen ist Mitinhaber dieser Anmeldungen zusammen mit den jeweiligen Institutionen. Reqorsa nutzt das TUSC2-Tumorsuppressorgen, das in nicht-viralen lipidbasierten Nanopartikeln verkapselt ist, die darauf ausgelegt sind, Krebszellen gezielt anzugreifen und gleichzeitig die Aufnahme durch normales Gewebe zu minimieren.
- Positive preclinical data supporting Reqorsa's potential to treat multiple cancer types
- Expansion of potential indications for Reqorsa to include Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma
- Filing of two provisional patent applications for treating mesothelioma and glioblastoma
- Collaboration with prestigious academic institutions for research
- Selective targeting of cancer cells by Reqorsa, with 10 to 33 times higher uptake compared to normal cells
- None.
The preclinical data presentations for Reqorsa® Gene Therapy across multiple cancer types are promising but preliminary. The focus on overcoming resistance in KRAS-mutant non-small cell lung cancer is particularly noteworthy, as KRAS mutations are common and challenging to treat. The expansion into mesothelioma and glioblastoma suggests potential broader applications.
However, it's important to remember that preclinical results often don't translate directly to human trials. The
The potential of Reqorsa® to address Ras inhibitor resistance in lung cancer is clinically significant. Resistance to targeted therapies remains a major challenge in oncology and novel approaches are desperately needed. The expansion into mesothelioma and glioblastoma is also exciting, as these are aggressive cancers with treatment options.
The TUSC2 gene therapy approach is innovative, potentially offering a new mechanism to combat cancer cell growth. However, we must be cautious. Gene therapy has shown promise in preclinical stages before, only to face significant hurdles in human trials. Safety, delivery efficiency and durable response in patients will be critical factors to watch as this therapy progresses through clinical development.
While the preclinical data is encouraging, investors should remain cautious. Genprex is still in early stages and the path to commercialization is long and uncertain. The company's focus on multiple cancer types could be seen as either diversifying risk or spreading resources too thin.
The filing of provisional patents is a positive step for protecting intellectual property, but it's important to note that Genprex is co-owning these with academic institutions, which could impact future royalties. The company's financial position and burn rate will be important factors to monitor as they move towards more expensive clinical trials. Without revenue-generating products, Genprex may need to seek additional funding, potentially diluting existing shareholders.
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma
"We are very pleased that these studies with our academic partners have been selected for presentation, which expands the growing body of preclinical evidence supporting REQORSA's potential to treat a variety of cancers," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to these presentations next month which will share the compelling data that support the potential for new clinical studies evaluating Reqorsa as a potential treatment for additional types of lung cancer, mesothelioma and glioblastoma."
Featured Genprex-supported posters to be presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:
Title: "TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib"
Collaborator: The University of Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372
Title: "TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells"
Collaborator: New York University Langone Health
Catalog Number: 364
Presentation Number: PB352
Title: "Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas Health Science Center at
Catalog Number: 130
Presentation Number: PB118
Genprex has filed two provisional patent applications based on data from two of the presentations. One application involves using REQORSA to treat mesothelioma and the other to treating glioblastoma. Genprex is a co-owner of the applications along with the respective institutions. TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302241636.html
SOURCE Genprex, Inc.
FAQ
What is Genprex's lead drug candidate and what cancers is it being studied for?
What recent patent applications has Genprex (GNPX) filed related to Reqorsa?
How does Reqorsa target cancer cells specifically?
When and where will Genprex's (GNPX) research collaborators present their findings on Reqorsa?
